Ethionamide population pharmacokinetics/pharmacodynamics and therapeutic implications in South African adult patients with drug‐resistant tuberculosis

• Published in: British journal of clinical pharmacology 2021-10, Vol.87 (10), p.3863-3870
• Main Authors: Mugabo, Pierre, Mulubwa, Mwila
• Format: Article
• Language: English
• Subjects: drug‐resistant tuberculosis; ethionamide; pharmacokinetics
• ISSN: 0306-5251; 1365-2125
• DOI: 10.1111/bcp.14795

Introduction Ethionamide is part of the drug‐resistant tuberculosis regimen whose pharmacokinetic (PK) and pharmacodynamic (PD) information is limited. The aim of the study was to describe the PK and simulate doses to assess PD attainment. Methods This was an observational population PK study of patients admitted for drug‐resistant tuberculosis at a hospital in South Africa. Nonlinear mixed‐effects modelling implemented in Monolix 2019R2 was used to estimate population pharmacokinetic parameters. We performed Monte Carlo simulations to assess and optimise the dose regimen. The target Cmax range was 2.5‐5 μg/mL, which is within the minimum inhibitory concentration (MIC) range. The target AUC0‐24h was 140.5 μg*h/mL, which corresponds to the PK/PD target ratio AUC0‐24h/MIC of 56.2. Results A one‐compartment pharmacokinetic model with a lag‐time, first‐order absorption and elimination best described the PK of ethionamide. The lag‐time, absorption rate constant (ka), volume of distribution (V/F) and clearance (Cl/F) were 0.66 hours, 0.434 h−1, 180 L and 99.5 L/h, respectively, for a typical individual weighing 52.6 kg. Between‐subject variability in lag‐time, ka, V/F and Cl/F were 38%, 92%, 168% and 120%, respectively. Simulation of the recommended doses of 15‐20 mg/kg, 500 mg, 750 mg and 1000 mg for patients in the weight bands 70 kg resulted in